πŸ‡ΊπŸ‡Έ FDA
Patent

US 11820775

Pyrrolopyrimidine ITK inhibitors

granted A61KA61K45/06A61P

Quick answer

US patent 11820775 (Pyrrolopyrimidine ITK inhibitors) held by Aclaris Therapeutics, Inc. expires Mon Nov 16 2043 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Aclaris Therapeutics, Inc.
Grant date
Tue Nov 21 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Nov 16 2043 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
34
CPC classes
A61K, A61K45/06, A61P, A61P29/00, A61P37/00